Newsroom | 52828 results

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck’s anti-PD-1 therapies, each in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of adult patients with muscle-invasive bla...

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant and adjuvant (before and after surgery) treatment for adult patient...

DOVER, Del.--(BUSINESS WIRE)--Precisio announced the continuation of its expanded access program, with dosing of a staph lysin called ClyO (LYSG101) to a patient with chronic prosthetic joint infection. Under an FDA-approved expanded-access IND, administration of ClyO was initiated on June 1. The treatment follows a 4 month protocol with a minimum 6 month follow-up. Outcomes to be tracked include safety, improvements of clinical signs and symptoms, and either durable eradication or sustained sup...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan...

سان ماتيو، كاليفورنيا--(BUSINESS WIRE)--أسهمت أول تجربة سريرية عشوائية محكمة (RCT) من نوعها، نُشرت اليوم في مجلة Schizophrenia Bulletin، وأجراها باحثون من جامعة كاليفورنيا في سان فرانسيسكو (UCSF) بتمويل جزئي من المعهد الوطني للصحة النفسية (NIMH)، في إثراء قاعدة الأدلة العلمية المتزايدة التي تشير إلى الفوائد المحتملة للنظام الغذائي الكيتوني في علاج الاضطرابات الذهانية. وأظهرت الدراسة، التي ضمّت مشاركين مصابين باضطرابات طيف الفصام أو اضطراب ثنائي القطب من النوع الأول، أن اتباع النظام الغذائي الكيت...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employee options to purchase a total of 16,060 shares of the Company’s common stock at an exercise price per share of $30.26, which was the...

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, announced that beginning October 1, 2026, eligible Anthem® Blue Cross® and Blue Shield® members will be the first in the United States to receive insurance coverage under a medical policy for the PrecivityAD2® blood test. This policy expands patient access to an innovative blood-based diagnostic test that helps health care professionals evaluate adults exp...

MIAMI & NEW YORK--(BUSINESS WIRE)--OpenEvidence, a medical AI and clinical decision support tool for U.S. clinicians, today announced a collaboration with NewYork-Presbyterian and its affiliated medical schools, Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine, to deploy OpenEvidence across all hospitals and care sites throughout the Greater New York region. This enterprise-scale collaboration will place trusted, evidence-based clinical AI in the hands o...

BOSTON--(BUSINESS WIRE)--Studion, a technology services company that envisions, designs, and builds engaging digital experiences for Learning and Life Sciences, today announced the promotion of Brian Harrington to General Manager of its Life Sciences business unit. In this expanded role, Harrington will lead the strategy, growth, and delivery of Studion's end-to-end eClinical services, helping life sciences organizations accelerate time to market for life-changing treatments. Harrington brings...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its CEO, Rob Fried, will participate in a virtual fireside chat hosted by KCSA Strategic Communications on Wednesday, July 15, 2026, at 8 am PDT. During the discussion, Mr. Fried will discuss the recently launched pharmaceutical program for rare genetic diseases and aging-related disorders, the C...